Want to see AURX full AI Analyst Report?
AURX Stock Chart & Stats
$1.07
$0.00(0.00%)
At close: 4:00 PM EST
$1.07
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.77 - $3.23
Previous CloseN/A
Volume8.36K
Average Volume (3M)3.48K
Market Cap
$58.60M
Enterprise Value$47.83
Total Cash (Recent Filing)$449.32K
Total Debt (Recent Filing)$1.50M
Price to Earnings (P/E)―
Beta-0.79
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,433,777
10 Day Avg. Volume8,403
30 Day Avg. Volume3,478
Financial Highlights & Ratios
PEG Ratio-10.00
Price to Book (P/B)-97.44
Price to Sales (P/S)28.13
P/FCF Ratio-81.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginSharp TTM revenue growth alongside a roughly 64% gross margin indicates stronger commercial traction and meaningful unit economics. If maintained, this combination can expand the revenue base and provide more gross-profit dollars to support investment in Aurix and eventual operating leverage.
Improving Loss ProfileLosses have improved versus prior years, showing progress even though profitability remains distant. Continued improvement could reduce the scale of future losses, preserve capital for development and commercialization, and strengthen the company’s potential path toward break-even over time.
Improving Free Cash Flow TrendFree cash flow has improved versus the prior annual period, and cash burn is less severe than earlier years. If sustained, this trend could reduce the external funding required to maintain operations while the company develops commercial traction and advances its regenerative medicine business.
Bears Say
Persistent UnprofitabilityEBIT margin near -30% and net margin near -39% show that stronger sales have not yet translated into a sustainable profit engine. Continued losses can consume capital, limit internally funded growth, and increase dependence on financing while the company pursues commercialization.
Negative Equity And Rising DebtNegative stockholders’ equity and rising debt create a strained capital structure with limited financial flexibility. This increases leverage and solvency risk, leaves less capacity to absorb operating setbacks, and makes future growth more reliant on external capital rather than internally generated resources.
Ongoing Cash ConsumptionNegative operating and free cash flow across TTM and recent annual periods shows that the business still consumes cash to operate and invest. Unless losses and cash usage improve further, continued funding needs could constrain strategic flexibility and increase financing pressure.
Nuo Therapeutics News
AURX FAQ
What was Nuo Therapeutics’s price range in the past 12 months?
Nuo Therapeutics lowest stock price was $0.77 and its highest was $3.23 in the past 12 months.
What is Nuo Therapeutics’s market cap?
Nuo Therapeutics’s market cap is $58.60M.
When is Nuo Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nuo Therapeutics’s earnings last quarter?
Currently, no data Available
Is Nuo Therapeutics overvalued?
According to Wall Street analysts Nuo Therapeutics’s price is currently Overvalued.
Does Nuo Therapeutics pay dividends?
Nuo Therapeutics does not currently pay dividends.
What is Nuo Therapeutics’s EPS estimate?
Nuo Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuo Therapeutics have?
Nuo Therapeutics has 48,433,777 shares outstanding.
What happened to Nuo Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nuo Therapeutics?
Currently, no hedge funds are holding shares in AURX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuo Therapeutics
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.